Press Releases Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
28.38 ^USD	-2.31%		+0.67%	-15.89%

14/05	Transcript : Pacira BioSciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
10/05	Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference	30/05	GL
PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $250.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.125% CONVERTIBLE SENIOR NOTES DUE 2029	13/05	AQ
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029	10/05	GL
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029	10/05	AQ
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes	09/05	GL
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes	09/05	AQ
Pacira BioSciences : 1Q 2024 Earnings Presentation	08/05	PU
Pacira: Q1 Earnings Snapshot	08/05	AQ
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program	08/05	GL
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	07/05	GL
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024	30/04	GL
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02/04	GL
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03	AQ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03	GL
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03	AQ
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	06/03	GL
Pacira: Q4 Earnings Snapshot	29/02	AQ
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02	GL
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	22/02	GL
Pacira to Report 2023 Financial Results on Thursday February 29, 2024	22/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Press Releases

Filters